Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.
作者信息
Remacha Angel F, Arrizabalaga Beatriz, Bueno Javier, Muñoz Juan, Bargay Joan, Pedro Carme
出版信息
Haematologica. 2010 Feb;95(2):339-40. doi: 10.3324/haematol.2009.016956.
Abstract
摘要
相似文献
1
Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.对促红细胞生成素治疗耐药的低危骨髓增生异常综合征患者，先用霉酚酸酯治疗，随后使用重组人促红细胞生成素。
Haematologica. 2010 Feb;95(2):339-40. doi: 10.3324/haematol.2009.016956.
2
Successful treatment of steroid-resistant minimal change disease with mycophenolate mofetil.霉酚酸酯成功治疗激素抵抗型微小病变病
Am J Nephrol. 2002 Sep-Dec;22(5-6):569-72. doi: 10.1159/000065276.
3
Using mycophenolate mofetil in steroid-resistant nephrotic syndrome.在激素抵抗型肾病综合征中使用吗替麦考酚酯。
Iran J Kidney Dis. 2012 Sep;6(5):323-5.
4
[Response to mycophenolate mofetil in a case of lupus nephropathy resistant to cyclophosphamide IV and cyclosporin A].
Nefrologia. 2001 Sep-Oct;21(5):516-7.
5
Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil.霉酚酸酯治疗掌跖部顽固性盘状红斑狼疮。
J Am Acad Dermatol. 2001 Jul;45(1):142-4. doi: 10.1067/mjd.2001.114297.
6
Efficacy of mycophenolate mofetil for steroid and cyclosporine resistant membranoproliferative glomerulonephritis type I.霉酚酸酯治疗对类固醇和环孢素耐药的Ⅰ型膜增生性肾小球肾炎的疗效。
Pediatr Nephrol. 2009 Aug;24(8):1593-4. doi: 10.1007/s00467-009-1141-x. Epub 2009 Feb 18.
7
[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].霉酚酸酯：皮肤科一种新型免疫抑制药物及其可能的用途
Hautarzt. 2000 Feb;51(2):63-9. doi: 10.1007/s001050050013.
8
Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination.使用西罗莫司和霉酚酸酯联合进行无钙调神经磷酸酶抑制剂的移植物抗宿主病预防
Ann Hematol. 2017 Sep;96(9):1563-1568. doi: 10.1007/s00277-017-3062-2. Epub 2017 Jul 15.
9
Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes.人重组促红细胞生成素治疗骨髓增生异常综合征患者
Br J Haematol. 1992 Aug;81(4):628-30. doi: 10.1111/j.1365-2141.1992.tb03014.x.
10
Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes.重新审视重组促红细胞生成素在骨髓增生异常综合征中的应用。
Clin Lymphoma. 2005 Jun;6(1):52-5. doi: 10.3816/clm.2005.n.029.
引用本文的文献
1
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.免疫抑制治疗在骨髓增生异常综合征治疗中的应用：系统评价和荟萃分析。
Haematologica. 2020 Jan;105(1):102-111. doi: 10.3324/haematol.2019.219345. Epub 2019 Apr 19.
2
Immune Mechanisms in Myelodysplastic Syndrome.骨髓增生异常综合征中的免疫机制
Int J Mol Sci. 2016 Jun 15;17(6):944. doi: 10.3390/ijms17060944.
3
Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.在来自 SKM-1 和 MOLM-13 白血病细胞系的阿扎胞苷耐药细胞系中，肌苷-5'-单磷酸脱氢酶抑制剂 FF-10501 缺乏交叉耐药性。
Pharmacol Res Perspect. 2016 Jan 28;4(1):e00206. doi: 10.1002/prp2.206. eCollection 2016 Feb.
本文引用的文献
1
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.骨髓增生异常综合征病理生理学中的自身免疫机制及其临床相关性。
Haematologica. 2009 Apr;94(4):449-51. doi: 10.3324/haematol.2009.006080.
2
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.根据世界卫生组织标准分类的骨髓增生异常综合征的预后因素和预期寿命：临床决策的基础
J Clin Oncol. 2005 Oct 20;23(30):7594-603. doi: 10.1200/JCO.2005.01.7038. Epub 2005 Sep 26.
3
Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study.霉酚酸酯治疗成人难治性自身免疫性血细胞减少症的疗效：一项单中心初步研究。
Eur J Haematol. 2005 Jul;75(1):60-4. doi: 10.1111/j.1600-0609.2005.00437.x.
4
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.使用促红细胞生成素和粒细胞集落刺激因子治疗骨髓增生异常综合征贫血的长期结果
Blood. 2005 Aug 1;106(3):803-11. doi: 10.1182/blood-2004-10-3872. Epub 2005 Apr 19.
5
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.8号染色体三体骨髓增生异常综合征患者中，自体淋巴细胞对8号染色体三体的抑制作用优于对正常造血细胞生长的抑制作用。
Blood. 2005 Aug 1;106(3):841-51. doi: 10.1182/blood-2004-05-2017. Epub 2005 Apr 12.
6
Immunosuppressive treatments for myelodysplastic syndromes.
Leuk Lymphoma. 2003 Apr;44(4):593-604. doi: 10.1080/1042819021000055345.
7
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.一种用于治疗骨髓增生异常综合征贫血的经验证的决策模型：促红细胞生成素+粒细胞集落刺激因子对生活质量有显著影响。
Br J Haematol. 2003 Mar;120(6):1037-46. doi: 10.1046/j.1365-2141.2003.04153.x.
8
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.抗胸腺细胞球蛋白对未经选择的骨髓增生异常综合征贫血患者疗效有限且毒性较大。
Blood. 2003 Mar 15;101(6):2156-8. doi: 10.1182/blood-2002-09-2867. Epub 2002 Oct 31.
9
Zotero 插件